Literature DB >> 31632768

Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical.

Megan Greally1, Geoffrey Y Ku1.   

Abstract

Entities:  

Year:  2019        PMID： 31632768      PMCID： PMC6783756          DOI： 10.21037/jtd.2019.08.116

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Authors:  Akira Tsuburaya; Kazuhiro Yoshida; Michiya Kobayashi; Shigefumi Yoshino; Masazumi Takahashi; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoto Takahashi; Hiroshi Imamura; Naokuni Tatsumoto; Akinori Hara; Kazuhiro Nishikawa; Ryoji Fukushima; Isao Nozaki; Hiroshi Kojima; Yumi Miyashita; Koji Oba; Marc Buyse; Satoshi Morita; Junichi Sakamoto
Journal:  Lancet Oncol       Date:  2014-06-18       Impact factor: 41.316

2.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Authors:  Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

4.  Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.

Authors:  Yoon Young Choi; Hyunki Kim; Su-Jin Shin; Ha Yan Kim; Jinae Lee; Han-Kwang Yang; Woo Ho Kim; Young-Woo Kim; Myeong-Cherl Kook; Young Kyu Park; Hyung-Ho Kim; Hye Seung Lee; Kyung Hee Lee; Mi Jin Gu; Seung Ho Choi; SoonWon Hong; Jong Won Kim; Woo Jin Hyung; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

5.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

6.  Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Authors:  Charles S Fuchs; Donna Niedzwiecki; Harvey J Mamon; Joel E Tepper; Xing Ye; Richard S Swanson; Peter C Enzinger; Daniel G Haller; Tomislav Dragovich; Steven R Alberts; Georg A Bjarnason; Christopher G Willett; Leonard L Gunderson; Richard M Goldberg; Alan P Venook; David Ilson; Eileen O'Reilly; Kristen Ciombor; David J Berg; Jeffrey Meyerhardt; Robert J Mayer
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

7.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Authors:  Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

8.  Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group.

Authors:  Mary Armanios; Ronghui Xu; Arlene A Forastiere; Daniel G Haller; John W Kugler; Al B Benson
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

9.  Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.

Authors:  R C Fields; V E Strong; M Gönen; K A Goodman; N P Rizk; D P Kelsen; D H Ilson; L H Tang; M F Brennan; D G Coit; M A Shah
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

10.  Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Authors:  Elizabeth C Smyth; Matteo Fassan; David Cunningham; William H Allum; Alicia F C Okines; Andrea Lampis; Jens C Hahne; Massimo Rugge; Clare Peckitt; Matthew Nankivell; Ruth Langley; Michele Ghidini; Chiara Braconi; Andrew Wotherspoon; Heike I Grabsch; Nicola Valeri
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.